Clinical Trial News and Research

RSS

New study: Coronary calcium scan can help reduce risk of heart disease

A new study of coronary artery calcium scanning - a simple, noninvasive test that gives patients baseline information about plaque in their coronary arteries—has shown that the scan helps them make heart-healthy lifestyle changes and lower their heart disease risk factors.

24 Mar 2011

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead Sciences, Inc. today announced that the Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

Almac to launch new services for clinical trial patient management

Almac announced today that its Clinical Technologies business unit, a global leader in clinical trial management, will launch a suite of new services designed to improve patient compliance and retention in clinical trials.

23 Mar 2011

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

23 Mar 2011

Artificial disc replacement may provide better long-term results at reduced cost

When physical therapy and drugs fail to relieve back or neck pain, patients often turn to spinal fusion surgery as a last resort, but two new studies show that in certain situations, especially when several discs are involved, artificial disc replacement may give better long-term results at lower cost.

23 Mar 2011

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia

Harvest Technologies Corp. announced today that the FDA has approved the company sponsored 210-patient IDE clinical trial to be conducted at twenty-five sites in the U.S. using the company's proprietary Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI).

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

SMR, RTU enter license agreement for RESCULA eye drops

Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, expanding Sucampo's rights beyond its previously agreed territory of the United States and Canada to all countries in Europe and the rest of the world except Japan, Korea, Taiwan and the People's Republic of China.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

DATATRAK fourth quarter revenue increases to 38%

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the fourth quarter and full year of 2010.

22 Mar 2011

Positive results from Meda's Dymista Phase III trial in patients with SAR

Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.

22 Mar 2011

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

22 Mar 2011